The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Upadacitinib Promising for RA in Phase 3 Study

Upadacitinib Promising for RA in Phase 3 Study

December 5, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A Phase 3, double-blind, placebo-controlled study evaluated upadacitinib (ABT-494) in rheumatoid arthritis (RA) patients who had an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Upadacitinib is an oral, selective JAK-1 inhibitor. In this study, which was presented at the 2017 ACR/ARHP Annual Meeting in San Diego, patients received 15 mg extended-release upadacitinib, 30 mg extended-release upadacitinib or placebo for 12 weeks—all once daily. The primary efficacy endpoints were the proportion of patients who achieved ACR20 response and the proportion who achieved DAS28-CRP low disease activity (≤3.2) at Week 12.1

You Might Also Like
  • Upadacitinib Promising for RA Patients
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Meets Study Endpoints to Treat RA
Also By This Author
  • Drug Updates

At Week 12, significantly more upadacitinib-treated patients compared with placebo-treated patients achieved ACR20 response (15 mg, 64%; 30 mg, 66%; placebo, 36%; P<0.001), as well as DAS28-CRP low disease activity (48%, 48% and 17.2%, respectively; P<0.001). The onset of action was rapid, with significantly more upadacitinib-treated patients achieving ACR20 at Week 1 compared with placebo-treated patients. At Week 12, significantly more 15 mg (38% and 21%) and 30 mg (43% and 27%) upadacitinib-treated patients met ACR50 and ACR70 criteria compared with placebo-treated patients (15% and 6%).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, significantly more upadacitinib-treated patients compared with placebo-treated patients obtained a DAS28-CRP <2.6 (15 mg, 31%; 30 mg, 28%; placebo, 10%; P<0.001). More upadacitinib-treated patients had significantly greater improvements in DAS28-CRP, HAQ-DI, morning stiffness and FACIT-F compared with placebo-treated patients.

Adverse events and serious adverse events occurred more frequently in upadacitinib-treated patients than in placebo-treated patients. The overall infection incidence was higher in upadacitinib-treated patients than in placebo-treated patients. Few serious infections occurred, and four cases of herpes zoster/varicella zoster virus infection occurred, one in a placebo-treated patient. Asymptomatic creatine phosphokinase elevations were reported only for upadacitinib-treated patients. Two malignancies and three adjudicated cardiovascular events were also reported. No deaths, tuberculosis cases or gastrointestinal perforations occurred. Types and frequency of laboratory abnormalities were similar to findings in the Phase 2 upadacitinib clinical trials.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Upadacitinib appears to be a promising oral agent in the treatment of RA for patients with an inadequate response to csDMARDs, with a quick onset of action, efficacy and minimal adverse events.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Burmester GR, Kremer J, van Den Bosch F, et al. A Phase 3 randomized, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective JAK-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs. [abstract]. Arthritis Rheumatol. 2017 Oct; 69(suppl 10).

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Rheumatoid Arthritis (RA), upadacitinib

You Might Also Like:
  • Upadacitinib Promising for RA Patients
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Meets Study Endpoints to Treat RA
  • Upadacitinib Monotherapy Effective in Refractory Rheumatoid Arthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.